Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.490
-0.180 (-10.78%)
At close: Jan 21, 2026, 4:00 PM EST
1.520
+0.030 (2.01%)
After-hours: Jan 21, 2026, 7:41 PM EST
Ocugen Employees
Ocugen had 95 employees as of December 31, 2024. The number of employees increased by 30 or 46.15% compared to the previous year.
Employees
95
Change (1Y)
30
Growth (1Y)
46.15%
Revenue / Employee
$56,526
Profits / Employee
-$673,895
Market Cap
465.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 95 | 30 | 46.15% |
| Dec 31, 2023 | 65 | -19 | -22.62% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 41 | 273.33% |
| Dec 31, 2020 | 15 | -1 | -6.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OCGN News
- 3 hours ago - Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering - Benzinga
- 11 hours ago - Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - GlobeNewsWire
- 6 days ago - Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript - Seeking Alpha
- 6 days ago - Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Benzinga
- 6 days ago - Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 8 days ago - Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - GlobeNewsWire
- 9 days ago - Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy - GlobeNewsWire
- 12 days ago - Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire